Sexual function and gonadal hormones in patients taking antipsychotic treatment for XXXX or @entity914 .

@entity1 @entity251 @entity1420 @entity914 @entity4090 @entity53 @entity161 @entity6126 @entity250
OBJECTIVE: To determine rates of @entity250 and @entity6126 and establish the relationship between gonadal hormone levels and sexual function in patients taking antipsychotic treatment for @entity161 or @entity914 . METHOD: We studied 103 @entity1 with @entity161 or @entity914 (mean age = 46.2 (SD = 12.9) years; 51.5% male) from October 2003 through March 2005. Sexual function was assessed using the Sexual Functioning Questionnaire (SFQ) and compared with (1) normal controls (N = 62; mean age = 36.1 (SD = 9.6) years; 55% male) recruited from primary care attendees and (2) sexually dysfunctional controls recruited from a local @entity250 (N = 57; mean age = 39.1 (SD = 10.7) years; 79% male). @entity4090 , sex hormone-binding globulin, @entity251 , @entity53 , @entity1420 , follicle-stimulating hormone, and luteinizing hormone levels; psychopathology; and side effects were measured. RESULTS: Mean (SD) total SFQ scores were significantly greater in @entity1 ( @entity1 = 9.9 [5.3]; @entity1 = 7.8 [4.9]) compared with normal controls ( @entity1 = 4.1 [2.9]; @entity1 = 4.09 [2.95]), and similar to the scores of @entity250 attendees ( @entity1 = 7.2 [2.9]; @entity1 = 9.9 [4.5]). The odds ratios of @entity1 having @entity250 compared with normal controls were 15.2 for @entity1 and 3.7 for @entity1 . @entity6126 was common (in premenopausal @entity1 , 79% showed hypoestrogenism and 92% showed low @entity1420 levels, and 28% of @entity1 showed hypotestosteronism). There was no association between total SFQ scores and @entity4090 or gonadal hormone levels. CONCLUSION: @entity1 receiving treatment for @entity161 or @entity914 show high rates of @entity250 and @entity6126 . Sexual functioning was not related to @entity4090 or gonadal hormone levels.
